• Citer

Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α Fragment antibody AZD9773 in Adult patients with severe sepsis and/or septic shock: Randomized, double-blind, placebo-controlled phase IIb Study

par Bernard, Gordon;François, Bruno;Mira, Jean-Paul;Vincent, Jean Louis ;Dellinger, Richard Phillip;Russell, James;LaRosa, Steven;Laterre, Pierre-Francois;Levy, Mitchell;Dankner, Wayne;Schmitt, Nicola;Lindemann, Justin;Wittebole, Xavier
Référence Critical care medicine, 42, 3, page (504-511)
Publication Publié, 2014-03

Article révisé par les pairs

• Détails
• Contenu

Titre:	Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α Fragment antibody AZD9773 in Adult patients with severe sepsis and/or septic shock: Randomized, double-blind, placebo-controlled phase IIb Study
Auteur:	Bernard, Gordon; François, Bruno; Mira, Jean-Paul; Vincent, Jean Louis; Dellinger, Richard Phillip; Russell, James; LaRosa, Steven; Laterre, Pierre-Francois; Levy, Mitchell; Dankner, Wayne; Schmitt, Nicola; Lindemann, Justin; Wittebole, Xavier
Informations sur la publication:	Critical care medicine, 42, 3, page (504-511)
Statut de publication:	Publié, 2014-03
Sujet CREF:	Soins intensifs réanimation
Mots-clés:	intensive care
	phase II
	polyclonal
	randomized controlled trial
	sepsis
	tumor necrosis factor-α
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0090-3493
	info:doi/10.1097/CCM.0000000000000043
	info:scp/84894456331